Experimental vaccine aims to boost immune attack on head and neck tumors
NCT ID NCT07572864
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the number of patients who have a major pathological response (fewer than 10% viable tumor cells after treatment). Only 9 participants will be enrolled at a single center in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Engineered mitochondrial vaccine (IMP3-Mito) and immune checkpoint inhibitor (PD-1 inhibitor)
What this could lead to
If successful, this combination could significantly improve tumor shrinkage before surgery and reduce recurrence risk for patients with head and neck cancer.
What could go wrong
This is a very small, early-phase trial with only 9 participants, so results may not apply broadly. The vaccine is experimental, and side effects from combining it with immunotherapy are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••